AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03961529
Drug: 1% OPA-15406 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT00381706
Drug: ECF
RxNorm normalized name: ECF-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin and 5-fluorouracil given IV
Trial: NCT00381706
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin , leucovorin and 5-fluorouracil IV
Trial: NCT01488734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the fortified mushroom arms
Trial: NCT01960764
Drug: Pre-Treatment with Dial liquid antibacterial soap
RxNorm normalized name: Dial Antibacterial Soap Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
Trial: NCT03069859
Drug: TXA (1g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
Trial: NCT02445352
Drug: Rosuvastatin 5mg
RxNorm normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02445352
Drug: DP-R207 5/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02445352
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02445352
Drug: DP-R207 10/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00792636
Drug: sumatriptan and naproxen sodium combination tablet
RxNorm normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sumatriptan 85mg and naproxen sodium 500mg
Trial: NCT00792636
Drug: naproxen sodium tablet
RxNorm normalized name: Naproxen Sodium Tablets
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 500mg
Trial: NCT02445352
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02445352
Drug: DP-R207 20/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02445352
Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
RxNorm normalized name: ezetimibe 10 MG / rosuvastatin 5 MG [Roszet]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02445352
Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02445352
Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02147431
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp.
Trial: NCT00816894
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
Trial: NCT01746641
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04005781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Trial: NCT03639064
Drug: Cannabis Oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil.
Trial: NCT01250236
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium hyaluronate 1.8mg/ml eye drops twice daily
Trial: NCT01860794
Drug: Mesencephalic Neuronal Precursor Cells
RxNorm normalized name: Bos taurus mesencephalon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
Trial: NCT03610867
Drug: Placebo (SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive the sample once by oral administration.
Trial: NCT00204672
Drug: Achipex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01468844
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg pink opaque capsule
Trial: NCT01468844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02975206
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT01100203
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
Trial: NCT01694459
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
Trial: NCT01694459
Drug: Standard dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
Trial: NCT02227290
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00992485
Drug: ADIPOPLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: autologous adipose-derived stem cell
Trial: NCT03016832
Drug: HuangKui Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuangKui Capsule 2.5g/tid, oral dosing.
Trial: NCT00144456
Drug: ED-71 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 μg/day(p.o.)for 144 weeks
Trial: NCT00002336
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03035058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03122639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Trial: NCT00141544
Drug: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESTRATEST® administered orally QD
Trial: NCT00078455
Drug: ILX651
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01209117
Drug: GSK2248761 WBM Capsule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg GSK2248761 WBM capsule (reference) 2 X100mg
Trial: NCT01209117
Drug: GSK2248761 WBM Tablet Formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 WBM Tablet 200mg manufacturing process 1
Trial: NCT01209117
Drug: GSK2248761 WBM Tablet Formulation 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 WBM Tablet 200mg manufacturing process 3
Trial: NCT01209117
Drug: GSK2248761 WBM Tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
Trial: NCT00277355
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
Trial: NCT01514149
Drug: CJC-1134-PC Injection
RxNorm normalized name: CJC-1295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJC-1134-PC administered weekly by subcutaneous injection
Trial: NCT01514149
Drug: Weekly placebo for CJC-1134-PC Injection
RxNorm normalized name: CJC-1295
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
Trial: NCT02141854
Drug: FS MDPI
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Trial: NCT02141854
Drug: Placebo MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Trial: NCT04737551
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
Trial: NCT00111046
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006185
Drug: Avandia administration for 6-12 weeks
RxNorm normalized name: lavandin oil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01091649
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ABT-450 / ritonavir see Arm Description for more information
Trial: NCT01091649
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ABT-450 / ritonavir See Arm Description for more information
Trial: NCT00518739
Drug: MK2461
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 \& beyond).
Trial: NCT02363322
Drug: B/Current Standard of Care Plus ZMapp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
Trial: NCT00667628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
Trial: NCT03756285
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 tablet taken orally for 90 days.
Trial: NCT03756285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally for 90 days.
Trial: NCT03395704
Drug: LJPC-401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
Trial: NCT03395704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Injection, USP, or equivalent
Trial: NCT03996993
Drug: Casodex, Axumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive hormone therapy if Axumin positive area appears.
Trial: NCT00430924
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily administration for 8 weeks and 8 weeks control.
Trial: NCT04547127
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT
Trial: NCT00983944
Drug: EPOCH regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV or orally
Trial: NCT00983944
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00983944
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or orally
Trial: NCT03452540
Drug: 1000mg DS102 (BID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
Trial: NCT02056743
Drug: CYP cocktail
RxNorm normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
Trial: NCT01380353
Drug: Diclofenac epolamine patch
RxNorm normalized name: Diclofenac Epolamine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].
Trial: NCT01448317
Drug: Placebo (Solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT00330577
Drug: placebo (artificial tears)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00075634
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00075634
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01813630
Drug: Genotropin®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04509635
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
Trial: NCT01153386
Drug: Treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treprostinil diethanolamine sustained release oral tablets.
Trial: NCT01906814
Drug: 3 cycles chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
Trial: NCT01906814
Drug: 6 cycles chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
Trial: NCT01839331
Drug: 4 mL Injection of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL Injection of Placebo
Trial: NCT01839331
Drug: 10 mL Injection of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL Injection of Placebo
Trial: NCT04215172
Drug: Macrolides
RxNorm normalized name: Macrolides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of azithromycin three times weekly for six months
Trial: NCT01228669
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
Trial: NCT00443794
Drug: Thiazides
RxNorm normalized name: Thiazides, plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule (blinded) oral administration once daily for 12 weeks
Trial: NCT00443794
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule (Blinded) for oral administration once daily for 12 weeks
Trial: NCT00772980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
Trial: NCT04177706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.
Trial: NCT00103935
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
Trial: NCT00103935
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
Trial: NCT00025090
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00366444
Drug: diclofenac potassium (XP21L)
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg every 6 hours
Trial: NCT00366444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 6 hours
Trial: NCT00025610
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025610
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00574834
Drug: HCTZ-hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCTZ 25 mg once daily for 6 months
Trial: NCT00220740
Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
Trial: NCT00713609
Drug: Clindamycin gel
RxNorm normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% clindamycin phosphate applied topically once a day
Trial: NCT00713609
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel is an identical gel without the active ingredients
Trial: NCT00713609
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is an identical cream without the active ingredients
Trial: NCT01009060
Drug: GSK239512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H3 Antagonist
Trial: NCT01009060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GSK239512
Trial: NCT00060528
Drug: Recombinant Fowlpox-GM-CSF
RxNorm normalized name: recombinant human GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00060528
Drug: Recombinant Human GM-CSF
RxNorm normalized name: recombinant human GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220740
Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
Trial: NCT00692042
Drug: AZD1704
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose, by mouth
Trial: NCT03539406
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclofosfamide/fludarabine treatment
Trial: NCT03259607
Drug: Nicorette Extra Mint 2 mg Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
Trial: NCT03259607
Drug: Nicorette Mint 2 mg Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.